Latest Headlines

  1. Ghana's First Precision Medicine Company Completes German Development Grant Programme, Delivering Measurable Impact Across Patient Access, Diagnostic Innovation, And Clean Energy 7/14/2026

    Revna Biosciences, Ghana's first precision medicine company, is contributing to transforming the landscape of healthcare in Ghana by offering advanced molecular tests for oncology, infectious diseases, etc. locally.

  2. Zoetis Announces Agreement To Acquire VitalRADS, Accelerating Diagnostic Capabilities 7/14/2026

    Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis announced in August 2025, this acquisition adds around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform.

  3. Roche Introduces Cobas Hepatitis D Virus (HDV) Test, The First Fully Automated Diagnostic Solution To Identify The Most Severe Form Of Viral Hepatitis 7/14/2026

    Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it introduces the cobas® HDV test for use on the cobas® 5800/6800/8800 systems, a diagnostic tool for the detection and quantification of Hepatitis D Virus (HDV) RNA, in countries accepting the CE mark.

  4. Castle Biosciences Announces New York State Department Of Health Approval Of Its AdvanceAD-Tx™ Test 7/14/2026

    Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH) for its AdvanceAD-Tx test.

  5. bioMérieux To Showcase Company's Latest In Diagnostic Innovations At ADLM 2026 7/14/2026

    bioMérieux, a global leader in in vitro diagnostics, today announced it will showcase its latest diagnostic solutions and innovations at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Conference & Clinical Lab Expo, taking place in Anaheim, California, July 26 through 30.

  6. Anthem Establishes Coverage Of C2N Diagnostics' PrecivityAD2 Blood Test For Alzheimer's Disease Evaluation 7/9/2026

    C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation, announced that beginning October 1, 2026, eligible Anthem Blue Cross and Blue Shield members will be the first in the United States to receive insurance coverage under a medical policy for the PrecivityAD2 blood test.

  7. The Jackson Laboratory, With The Broad Institute And Partners, Selected For ARPA-H THRIVE Award To Advance Gene Editing Platform For Pediatric Epilepsies And Rare CNS Diseases 7/9/2026

    The Jackson Laboratory (JAX) today announced it has been selected, with the Broad Institute and other partners, for an up to $34.5 million contract from the Advanced Research Projects Agency for Health (ARPA-H), within the U.S. Department of Health and Human Services (HHS), through its Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) initiative. 

  8. Renew Biotechnologies Unifies Wasatch BioLabs And Resonant Under One Brand To Advance Sequencing-Based Diagnostics 7/9/2026

    Renew Biotechnologies today announced the consolidation of Wasatch BioLabs and Resonant under the Renew Biotechnologies brand, creating a unified platform to advance sequencing-based diagnostics, translational research, and clinical testing.

  9. Roche Receives CE Mark For Blood Test To Identify Tuberculosis Infection 7/9/2026

    Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that its Elecsys IGRA TB test has received the CE Mark, introducing a new blood testing solution for identifying tuberculosis infection (TBI, also known as latent TB) in routine laboratory settings.

  10. NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic For Prostate Cancer 7/9/2026

    NeoGenomics, Inc., a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) for patients with prostate adenocarcinoma.